Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Optimi Health's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Optimi Health's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Optimi Health Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Optimi Health's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Optimi Health's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Optimi Health (FRA:8BN0) has a Buyback Yield % of 0.00 as of Jul. 14, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Optimi Health and its competitors. According to the industry distribution chart, Optimi Health ranks #999999 out of 290 companies in the Drug Manufacturers industry.
Is Optimi Health's Buyback Yield % too high?
Optimi Health's current Buyback Yield % is 0.00. Based on the distribution chart, Optimi Health ranks #999999 out of 290 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Optimi Health has a GF Score™ of 35/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Optimi Health's Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Optimi Health ranks #999999 out of 290 companies for Buyback Yield %. This places Optimi Health in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Optimi Health and its competitors. Optimi Health's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Optimi Health stock overvalued right now?
Based on GuruFocus' analysis, Optimi Health (FRA:8BN0) is currently considered Fairly Valued. The stock's GF Value™ is €3.51, compared to a current price of €3.87 — trading 10.3% above its estimated fair value. The current Buyback Yield % is 0.00. Optimi Health's overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Optimi Health (FRA:8BN0), the current Buyback Yield % is 0.00 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Optimi Health (FRA:8BN0) Overvalued in 2026?
Based on GuruFocus' analysis, Optimi Health stock appears to be overvalued.
The current stock price of €3.87 is trading 10.3% above its estimated GF Value™ of €3.51.
GuruFocus considers Optimi Health to be Fairly Valued.
Key valuation signals for FRA:8BN0:
Buyback Yield %: 0.00
GF Value™: €3.51 vs. price of €3.87 (10.3% above fair value)
No single metric tells the full story. See the FRA:8BN0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Optimi Health Corp operates in developing a vertically integrated Canadian functional mushroom brand that focuses on the health and wellness sector. The company has one reportable operating segment being that of the farming, processing, and distribution of raw mushroom biomass. It also intends to cultivate, extract, process, and distribute strains of fungi products at its facilities located in Princeton, British Columbia.
35GF Score
Get the complete analysis for FRA:8BN0
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8BN0 has been successfully added to your 
